APA (7th ed.) Citation

Wong, W., Adkins, D., Misleh, J., Lorch, J., Grewal, J., Russell, J., . . . Thomas, J. (2024). 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Annals of Oncology, 35, S622. https://doi.org/10.1016/j.annonc.2024.08.929

Chicago Style (17th ed.) Citation

Wong, W., et al. "868P Phase II Trial of Ozuriftamab Vedotin (BA3021), a Conditionally Active Biologic (CAB)-ROR2-ADC, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)." Annals of Oncology 35 (2024): S622. https://doi.org/10.1016/j.annonc.2024.08.929.

MLA (9th ed.) Citation

Wong, W., et al. "868P Phase II Trial of Ozuriftamab Vedotin (BA3021), a Conditionally Active Biologic (CAB)-ROR2-ADC, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)." Annals of Oncology, vol. 35, 2024, p. S622, https://doi.org/10.1016/j.annonc.2024.08.929.